Ads
related to: new treatment for aplastic anemia- About MDS and Anemia
Learn How MDS and Anemia Work
And What You Can Do
- MDS Treatment Option
Learn About This Treatment Option
For MDS-Related Anemia
- FAQs
Find Answers to Frequently Asked
Questions on This Treatment Option
- Get Financial Support
Find Information on Insurance,
Financing and Co-Pay Assistance
- 1L Treatment Results
Read About A Clinical Study On The
Results of A First Line Treatment
- 2L Treatment Results
Learn About The Results of A
Second Line Treatment Study
- About MDS and Anemia
Search results
Results From The WOW.Com Content Network
Aplastic anemia is a rare, noncancerous disorder in which the blood marrow is unable to adequately produce blood cells required for survival. [44] [45] It is estimated that the incidence of aplastic anemia is 0.7–4.1 cases per million people worldwide, with the prevalence between men and women being approximately equal. [46]
Eltrombopag, sold under the brand name Promacta among others, is a medication used to treat thrombocytopenia (abnormally low platelet counts) and severe aplastic anemia. [3][4] Eltrombopag is sold under the brand name Revolade outside the US and is marketed by Novartis. [5] It is a thrombopoietin receptor agonist. [3]
Pure red cell aplasia affects the red blood cells in particular. Pure red cell aplasia (PRCA) or erythroblastopenia refers to a type of aplastic anemia affecting the precursors to red blood cells but usually not to white blood cells. In PRCA, the bone marrow ceases to produce red blood cells. There are multiple etiologies that can cause PRCA.
Aplastic Anemia. Reticulocytopenia is the medical term for an abnormal decrease in circulating red blood cell precursors (reticulocytes) that can lead to anemia due to resulting low red blood cell (erythrocyte) production. [1] Reticulocytopenia may be an isolated finding or it may not be associated with abnormalities in other hematopoietic cell ...
The types of anemia treated with drugs are iron-deficiency anemia, thalassemia, aplastic anemia, hemolytic anemia, sickle cell anemia, and pernicious anemia, the most important of them being deficiency and sickle cell anemia with together 60% of market share because of highest prevalence as well as higher treatment costs compared with other ...
Hematology. Diamond–Blackfan anemia (DBA) is a congenital erythroid aplasia that usually presents in infancy. [3] DBA causes low red blood cell counts (anemia), without substantially affecting the other blood components (the platelets and the white blood cells), which are usually normal. This is in contrast to Shwachman–Bodian–Diamond ...
Ad
related to: new treatment for aplastic anemia